Colruyt Group N.V. : The pick-up is coming to an end
Entry price | Target | Stop-loss | Potential |
---|
€46.9 |
€40 |
€50.3 |
+14.71% |
---|
The technical chart pattern of the Colruyt stock clearly favors bearish reversal after a technical rebound over the last trading sessions.
Summary● In a short-term perspective, the company has interesting fundamentals.
Strengths● Considering the small differences between the analysts' various estimates, the group's business visibility is good.
● The company shows low valuation levels, with an enterprise value at 0.67 times its sales.
Weaknesses● According to Thomson-Reuters' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
● The company's earnings releases usually do not meet expectations.
● Revenue estimates are regularly revised downwards for the current and coming years.
● For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
● Most analysts recommend that the stock should be sold or reduced.
● The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
● The underlying tendency is negative on the weekly chart below the resistance at 47.83 EUR
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.